392 related articles for article (PubMed ID: 11408919)
1. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and progesterone receptors in ovarian epithelial tumors.
Lindgren PR; Cajander S; Bäckström T; Gustafsson JA; Mäkelä S; Olofsson JI
Mol Cell Endocrinol; 2004 Jun; 221(1-2):97-104. PubMed ID: 15223136
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ
Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341
[TBL] [Abstract][Full Text] [Related]
4. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis].
Han XY; Chen Y; Hou MM; Zhang J; Yang KX; Chen YY; Qie MR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):619-22, 634. PubMed ID: 18798508
[TBL] [Abstract][Full Text] [Related]
5. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
[TBL] [Abstract][Full Text] [Related]
9. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis B; Agnantis NJ
Anticancer Res; 2004; 24(3a):1665-70. PubMed ID: 15274338
[TBL] [Abstract][Full Text] [Related]
10. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
13. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
[TBL] [Abstract][Full Text] [Related]
14. [Study of effect of mifepristone on apoptosis of human ovarian cancer cell line 3AO].
Li Q; Li JJ; Zhao XB; Ji M
Zhonghua Fu Chan Ke Za Zhi; 2003 Oct; 38(10):625-8. PubMed ID: 14728868
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
16. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
19. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
[TBL] [Abstract][Full Text] [Related]
20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
